$AIM 08:55 on Feb. 23 2026 AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

$ALUR 09:00 on Feb. 23 2026 Allurion Receives U.S. FDA Approval

$TIRX 09:15 on Feb. 23 2026 TIAN RUIXIANG in Advanced Talks to Combine With An Asia-Pacific Leading InsurTech In Addition to Advancing Its 15,000 Bitcoin Acquisition Strategy

$LRMR 07:00 on Feb. 24 2026 Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

$DTCK 09:30 on Feb. 24 2026 Davis Commodities Strengthens Revenue Visibility with US$20 Million Pipeline from Leading International Food Trade Exhibition

$DOCU 09:30 on Feb. 24 2026 Docusign Partners with Anthropic to Bring Its Intelligent Contract Workflows to Cowork